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Abstract: Even though coronavirus infection of humans is not normally associated with severe diseases, the identification 
of the coronavirus responsible for the outbreak of severe acute respiratory syndrome showed that highly pathogenic 
coronaviruses can enter the human population. Shortly thereafter, in Holland in 2004, another novel human coronavirus 
(HCoV-NL63) was isolated from a seven-month old infant suffering from respiratory symptoms. This virus has 
subsequently been identified in various countries, indicating a worldwide distribution. HCoV-NL63 has been shown to 
infect mainly children and the immunocommpromised, who presented with either mild upper respiratory symptoms 
(cough, fever and rhinorrhoea) or more serious lower respiratory tract involvement such as bronchiolitis and croup, which 
was observed mainly in younger children. In fact, HCoV-NL63 is the aetiological agent for up to 10% of all respiratory 
diseases. This review summarizes recent findings of human coronavirus HCoV-NL63 infections, including isolation and 
identification, phylogeny and taxonomy, genome structure and transcriptional regulation, transmission and pathogenesis, 
and detection and diagnosis. 
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1. INTRODUCTION 
  Regardless of geographic location, respiratory tract 
infections rank among the top three killers of children under five 
years of age [1]. A significant proportion of these respiratory 
tract infections have no known cause. Recently, however, a 
number of novel coronaviruses have been identified as the 
causative agents for some of these infections [2, 3]. 
 Coronaviruses (CoVs) belong to the family 
Coronaviridae in the order nidovirales. Members of the 
Coronavirus family are positive-strand RNA viruses with 
large genomes ranging in size from 27–33 kb. The 
coronavirus genome encodes for a 5 replicase polyprotein 
(ORF1a and ORF1b) that, in turn, encodes for all the 
enzymes required for viral RNA replication. The genome 
also encodes for the 3 structural proteins, including spike 
(S), envelope (E), membrane (M) and nucleocapsid (N), 
which are common to all coronaviruses. The structural 
proteins are involved in various viral processes, including 
virus particle formation [4]. Additional subgroup-specific 
accessory genes are found interspersed among the structural 
genes, which vary in number and location. Recent studies 
have shown that the proteins encoded by these genes could 
be modulators of pathogenicity in the natural host [5-7]. 
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  Five human coronaviruses have been identified to date, 
four of which are known to continuously circulate in the 
human population, especially in young children [8, 9]. 
HCoV-OC43 and HCoV-229E, first identified in the mid-
1960s [10, 11], were shown to cause the common cold [12], 
but rarely infections of the lower respiratory tract [3]. A third 
human coronavirus, which causes severe acute respiratory 
syndrome, SARS-CoV, was identified in 2003 [13, 14]. This 
virus had a worldwide spread, causing acute respiratory 
illness with a mortality rate of ~10% [15]. The last reported 
SARS-CoV infections were laboratory acquired in 2004, and 
the virus has not been detected in the human population 
since [16, 17]. More recently, two additional human 
coronaviruses were identified; HCoV-HKU1 was isolated 
from a 71-year-old man who presented with fever and cough 
[3], and HCoV-NL63 isolated from a seven-month-old baby 
[2]. The latter is the topic of this review. 
  Several groups have studied different aspects of HCoV-
NL63 infections, including its worldwide distribution, its 
association with human disease, and the replication 
characteristics of the causative virus. In this review we 
summarize recent findings of human coronavirus HCoV-
NL63 infections, including virus isolation and identification, 
phylogeny and taxonomy, genome structure and 
transcriptional regulation, transmission and pathogenesis, 
and detection and diagnosis. 
2. ISOLATION AND IDENTIFICATION OF HCoV-
NL63 
  HCoV-NL63 was first isolated in Amsterdam in 2004 
from the nasopharyngeal aspirate of a seven-month old child; 
the patient presented with symptoms suggesting respiratory Understanding Human Coronavirus HCoV-NL63  The Open Virology Journal, 2010, Volume 4    77 
tract infection (coryza, conjunctivitis, and fever), while his 
chest X-ray showed typical features of bronchiolitis. The 
aspirate tested negative for all known respiratory viruses. A 
group of Dutch scientists found that the virus initiated a 
cytopathic effect when inoculated onto tertiary monkey 
kidney cells. The group used a new technique, VIDISCA, to 
clone and amplify the viral genome. VIDISCA is a novel 
approach that provides a fast and effective tool for 
amplification of unknown genomes based on cDNA-
amplified fragment length polymorphism [2, 18]. The virus 
was identified as a member of the Coronaviridae family. It 
was shown to be a novel member of Group I coronaviruses 
because of the similarity of its genome sequence to HCoV-
229E. Another group in the Netherlands [19] reported the 
independent isolation and identification of, essentially, the 
same virus at about the same time. 
3. PHYLOGENY AND TAXONOMY OF HCoV-NL63 
  Based on antigenicity, genome organization and 
sequence homology, coronaviruses are divided into three 
distinct groups [20]. Group 1 contains transmissible 
gastroenteritis virus (TGEV), porcine epidemic diarrhea 
virus (PDEV), feline infectious peritonitis virus (FIPV), 
canine coronavirus and HCoV-229E, among others. Group 2 
contains mouse hepatitis virus (MHV), bovine coronavirus, 
haemagglutinating encephalomyelitis virus, HCoV-HKU1 
and HCoV-OC43, to name a few, with Bat SARS-CoV and 
SARS-CoV considered distantly related Group 2b 
coronaviruses. Group 3 contains the avian coronaviruses [21-
23]. Based on phylogenetic analysis, HCoV-NL63 belongs 
to the Group I coronaviruses [2, 24]. Interestingly, evidence  
 
of recombination during the evolution of HCoV-NL63 has 
been reported, and viral isolates have, in fact, a mosaic 
genome structure. The authors speculate that HCoV-NL63 
diverged from a HCoV-229E ancestor in the past, followed 
by a separation into two distinct HCoV-NL63 lineages. 
These two lineages recombined during co-infection, giving 
rise to the two currently observed genotypic subgroups [24-
27]. In fact, recombination between different HCoV-NL63 
isolates has been suggested, resulting in a mixture of clinical 
virus variants circulating in the human population [8, 27-30]. 
3.1. Genome Structure and Transcriptional Regulation 
  HCoV-NL63 has a single-stranded RNA genome that is 
capped and polyadenylated [27]. The genome is 27553 bases 
in size, with the genome order 5-ORF1a-ORF1b-S-ORF3-E-
M-N-polyT-3 (Fig. 1). Seven distinct ORFs are produced 
from six distinct mRNAs, which include the full-length 
genomic RNA and a nested set of five subgenomic (sg) 
mRNAs [4]. Coronavirus mRNAs are generated in the 
membrane-associated replication centers [31]. The five sg 
mRNAs encode for the viral structural and accessory 
proteins S, ORF3, E, M and N. With the exception of ORF 
E, a common transcription regulatory sequence (TRS), with 
core sequence AACUAAA, is located upstream of all the 
ORFs; this TRS is crucial for sg mRNA formation [27, 32]. 
HCoV-NL63 uses a discontinuous replication strategy to 
generate sg mRNAs during the minus strand synthesis [4, 27, 
32], which are then copied into plus strand mRNAs. All plus 
strand mRNAs share a common ~70 nucleotide leader 
sequence at their 5’ ends that is identical to the sequence at 
the 5’ end of the genomic RNA [27]. 
 
Fig. (1). Schematic comparison of the genome organization of coronaviruses infecting humans. Genomic maps shown are based on the 
complete genome sequences (NCBI accession numbers are shown in brackets): HCoV-NL63: Human coronavirus HCOV-NL63 
(NC_005831); HCoV-229E: Human coronavirus 229E (NC_002645); SARS-CoV: Severe acute respiratory syndrome coronavirus 
(NC_004718); HKU1-CoV: Human coronavirus HKU1 (NC_006577); HCoV-OC43: Human coronavirus OC43 (NC_005147). ORFs S (1), 
E (2), M (3) and N (4) are shown and open reading frames encoding for accessory genes are shaded in grey. *ORF4 of HCoV-229E is shown 
as a single open reading frame [34]. 
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3.1.1. Protein 1a/1b 
  HCoV-NL63 ORF1a/1b contains a putative elaborated 
pseudoknot structure that triggers a -1 ribosomal frameshift 
to translate the complete 1ab polyprotein; for a mini-review 
of the putative ORF1a/1b products and functions see Pryc et 
al. (2007) [27] and Van der Hoek et al. (2006) [8]. Chen and 
colleagues identified processed products nsp3 and nsp4 of 
the HCoV-NL63 replicase polyprotein, which could be 
detected at 24 hours post-infection. These products localize 
in the peri-nuclear sites of virus infected cells. Also, the 
group identified and characterized two viral papain-like 
proteases, PLP1 and PLP2, which process the viral replicase 
polyprotein. Interestingly, the PLP2 protease has 
deubiquitinating activity [9], although the function of this is 
not clear in viral replication. 
3.1.2. Spike Protein 
  The species tropism and virulence of a particular 
coronavirus are largely determined by the spike (S) 
glycoprotein. Coronavirus S proteins mediate attachment to 
the cellular receptors and subsequent fusion of the virus and 
cell membrane [20]. The N-terminal portion of HCoV-NL63 
S contains a unique 179 amino acid domain not present in 
other coronaviruses. This region represents the most variable 
region of the HCoV-NL63 genome and a role in immune 
evasion for this region has been proposed [8, 27]. HCoV-
NL63 S is a single-chain glycoprotein and consists of an N-
terminal receptor-binding domain (S1) and a C-terminal 
transmembrane fusion domain (S2). S2 consists of two 
highly conserved heptad-repeat (HR) sequences that are 
larger than the corresponding regions for the group II and 
group III coronaviruses [20, 27, 33]. Initial proteolytic 
studies of the S2 fusion core identified an -helical domain 
consisting of a trimer of the HR segments N57 and C42. The 
resolved crystal structure of this trimeric complex shows 
distinctive high-affinity conformations of interacting cross-
sectional layers of six helices. It has been suggested that the 
larger HR regions of the group I coronaviruses may be 
required to prime the S proteins for their fusion-activating 
conformational changes during entry of the virus [20]. 
3.1.3. Accessory Protein ORF3 
  Coronavirus genomes contain accessory genes found 
interspersed among the structural genes, which vary in 
number and location between the different coronavirus 
groups (Fig. 1). Both HCoV-NL63 and HCoV-229E are 
group I coronaviruses and encode for only one accessory 
gene product between the S and E genes [34]. Accessory 
genes are poorly characterized and the functions of the gene 
products are not well understood. Initial research into the 
functions of these genes has shown that they are non-
essential and dispensable for virus growth in cell culture [5, 
6, 35]. More recent studies have shown that the accessory 
genes are required for in vivo infection and pathogenecity in 
the natural host [6, 7, 36-38]. 
  Unlike the SARS-CoV genome, the HCoV-NL63 
genome encodes for only one accessory protein, ORF3 (Fig. 
1). ORF3 is expressed from distinct subgenomic (sg) mRNA 
3, which is one of at least six distinct mRNAs [4]. The ORF3 
gene encodes for a putative 225 amino acid protein, about 
25.6 kDa in size. Pyrc et al. (2004) reports that the HCoV-
NL63 ORF3 gene has a unique nucleotide composition and 
appears as a U-rich and A-poor region within the genome, 
indicating a recent gene transfer event from another viral or 
cellular origin [4]. The ORF3 protein of HCoV-NL63 is 
homologous to proteins of the other Group 1 coronaviruses, 
with an amino acid sequence most similar (43% identity and 
62% similarity) to HCoV-229E ORF4. Based on 
comparative  in silico analysis of HCoV-NL63 ORF3 and 
other human coronavirus ORF3-like homologues, Fielding 
and Suliman speculate that the protein could contribute to 
pathogenesis in the natural host [39]. More recently, studies 
have shown that HCoV-NL63 localizes along the secretory 
pathway (ERGIC, Golgi, plasma membrane) and co-
localizes with the structural proteins M and E in the ERGIC. 
Also, studies have shown that this N-glycosylated protein is 
incorporated into virions during assembly. This further 
suggests an important function for HCoV-NL63 ORF3, 
particularly in virus assembly and/or budding from the 
infected cell [40]. 
4. TRANSMISSION AND PATHOGENESIS 
4.1. Mode of Entry into the Cell 
  It is well documented that SARS-CoV and HCoV-NL63 
use the same receptor, angiotensin converting enzyme 
(ACE)-2, for entry into the host cell [41, 42]. However, the 
consequences following the entry are very different; SARS-
CoV causes severe respiratory distress, while HCoV-NL63 
might lead to a mild respiratory infection. This was 
attributed to the ability of each virus receptor-binding 
protein, spike or S protein, to bind to ACE-2 on the cell 
surface. It was found that the HCoV-NL63 S protein has a 
weaker interaction with ACE-2 than the SARS-CoV S 
protein. This lower-affinity interaction with ACE-2 might 
partly explain the different pathological consequences of 
infection by SARS-CoV and HCoV-NL63 [43]. 
  Nevertheless, high pathogenicity is expected to evolve 
with coronaviruses. As for HCoV-NL63, the possibility of 
the development of a recombinant virus variant is high 
because of its high prevalence and the possibility of a 
recombination event through co-infection [24]. Moreover, 
the virus is able to survive for up to seven days in an 
aqueous solution and respiratory secretions and remains 
infective at room temperature. In heavily populated regions, 
direct person-to-person transmission is considered the major 
route of HCoV-NL63 spread [42, 44]. 
4.2. Seasonal Incidence 
  The virus has been shown to have a worldwide distribution 
and was observed primarily in the winter season in temperate 
climates. On the other hand, countries with extreme weather, 
like Canada, have also shown virus activity around January to 
March, although milder symptoms were reported [45]. 
Interestingly, seasonal variations have been reported in China 
where infection with HCoV-NL63 appeared mainly in spring 
and summer [26]. Also, a recent study of coronaviruses in 
Thailand did not show any seasonal predilection [46], while 
Wu et al. (2007) reported that the virus is detected during the 
autumn season in Taiwan [47]. It is evident that the virus has 
no predilection to a particular season and is not affected by 
temperature variations as infections can occur throughout the 
year (Table 1). Understanding Human Coronavirus HCoV-NL63  The Open Virology Journal, 2010, Volume 4    79 
4.3. Prevalence 
  The human coronaviruses account for a significant 
number of hospitalization for children under 18 years of age, 
the elderly and immunocompromised individuals. In fact, a 
one-year study of children hospitalized in Hong Kong 
(China) has shown that respiratory tract infection with 
coronaviruses accounts for 4.4% of all admissions for acute 
respiratory infections. Of these, HCoV-NL63 was the most 
common coronavirus identified with an incidence of 2.6% 
[48]. Moreover, a study in Japan has shown that out of 419 
specimens that tested negative for common respiratory 
viruses, five (1.2%) were positive for human coronavirus 
HCoV-NL63 [49]. Another Japanese report has indicated 
that out of 118 nasopharyngeal swab samples obtained from 
hospitalized children younger than two years of age, three 
(2.5%) were positive for HCoV-NL63 [50]. 
  In Europe, high prevalence was also noted. In Italy, a 
study conducted on 322 infants suffering from acute 
respiratory disease has shown that 8.7% of the cases 
examined were caused by coronaviruses, with HCoV-NL63 
accounting for 21.4% of the latter [51]. In France, 300 
respiratory specimens were checked for HCoV-NL63 
presence; of the 300 samples, 28 (9.3%) were positive [29]. 
Likewise, seven cases were reported in a one-year study in 
Belgium [28]. Interestingly, the Dutch group that first 
described the virus has obtained 949 samples from a German 
group who conducted a population-based study on lower 
respiratory tract infection in children under three years of age 
[52]; the group re-analyzed the samples and detected a 5.2% 
incidence of HCoV-NL63 [53]. In Australia, the virus was 
detected in Melbourne, where a study conducted on 543 
patients with respiratory symptoms has shown 18 cases 
(3.3%) of human coronavirus HCoV-NL63 infection [54]. 
Moreover, in the USA and Canada, the virus was reported in 
79 (8.8%) out of 895 and 19 (3.6%) out of 525 patients, 
respectively. 
  Currently, the accuracy of the percentage of detection is 
hampered by two main problems: firstly, the suitability of 
the samples examined: a recent study has shown that there 
are differences between respiratory samples collected by 
nose/throat swabs and by nasopharyngeal aspirates, 
specifically regarding their potential to detect and identify 
respiratory pathogens [55]. The second problem is that 
diagnostic tests for HCoVs are not frequently used in the 
routine testing for viruses, which probably results in the 
percentage of HCoVs infections being greatly 
underestimated [56]. Moreover, throughout the years several 
methods of variable sensitivity were used to determine the 
incidence of the virus [57-59]. 
4.4. Co-Infection 
  Many groups have reported that the occurrence of co-
infections with HCoV-NL63 and other respiratory viruses, 
including other human coronaviruses, influenza A virus, 
respiratory syncytial virus (RSV), parainfluenza virus and 
human metapneumovirus (hMPV), are common [26, 30, 46, 
47, 51, 53, 54, 60, 61]. Also, co-infected patients are more 
likely to be hospitalized, indicating the severity of this kind 
 
 
of superinfection. In a study from Germany, RSV-A and 
HCoV-NL63 was the most common co-infection indentified 
in children less than three years of age. This is probably due 
to the high incidence of RSV-A in winter and the overlap in 
seasonality of the viruses [53]. Also, in Italy, HCoV-NL63 
circulates as a mixture of variant strains and is often 
associated with other viral infections [30]. In South Africa, 
co-infection of patients with HCoV-NL63 and bocavirus in 
hospitalized children is reported. Nasopharyngeal and 
bronchoalveolar lavage samples from 341 patients were 
screened for common respiratory viruses, and the co-
presence of HCoV-NL63 and bocavirus in at least one 
sample was reported [62]. 
  Interestingly, the viral load of HCoV-NL63 is lower in 
co-infected patients than in patients infected with HCOV-
NL63 only. There are various possible explanations for this 
phenomenon [53]: 
1.  HCoV-NL63 might be the initial infection that 
weakens the immune system enough for a second 
infection to gain a foothold. By the time this second 
infection shows symptoms, the HCoV-NL63 infection 
might have already have been brought under control 
by the host immune system, 
2.  the two viruses may be in competition for the same 
receptor or target cell in the respiratory organs, 
3.  the elevated activation of the innate immune response 
triggered by the second respiratory virus may cause 
inhibition of HCoV-NL63 or, 
4.  prolonged persistence of HCoV-NL63 at low levels. 
  The high prevalence of co-infections of HCoV-NL63 and 
other respiratory viruses increases the chances of genetic 
recombination with these human or zoonotically transmitted 
viruses. In fact, Pryc et al. (2006) states HCoV-NL63 
resulted from a recombination event between PEDV and an 
ancestral HCoV-NL63 strain. Theoretically, these types of 
recombination events could enable highly pathogenic virus 
variants to arise [24]. 
4.5. Clinical Features 
  Recent scientific and clinical evidence has indicated that 
the virus is found during upper and lower respiratory tract 
infections, causing symptoms and signs that do not differ 
greatly from the symptoms described for the 'old' viruses 
HCoV-229E and HCoV-OC43. Other systems involvement 
is still controversial [63]. 
 Table  1 shows that patients diagnosed with the virus have 
presented with mild symptoms, indicating upper respiratory 
tract infection such as fever, cough and rhinorrhoea. On the 
other hand, the disease is also known to cause significant 
more alarming lower respiratory tract infection. One of the 
most alarming symptoms is bronchiolitis, an inflammation of 
the membranes lining the bronchioles. This symptom was 
reported by several research groups [25, 50, 64], and 
although a population-based study in China did not report an 
association of HCoV-NL63 with bronchiolitis [26], it is still 
believed to be one of the presenting symptoms. Several 
research groups have linked HCoV-NL63 to croup [26, 53].  
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Table 1.  Epidemiological, Demographic, Clinical and Virological Characteristics of HCoV-HCOV-NL63 Infections 
 
Country  Specimen 
Type 
Method of 
Detection 
Seasonal 
Prevalence 
Type of 
Study 
Number of 
Patients 
Involved in 
the Study 
(Sample 
Size) 
Age 
Incidence 
of HCoV-
NL63 
Co-
Infection  Symptoms  Refs. 
Australia  Throat and nose 
swab  RT-PCR  Winter  Community 
based  234  > 5 years  3.3%  ND 
Mild 
No croup,  
No bronchiolitis 
[54] 
Belgium NR  RT-PCR 
Winter 
(January- 
February) 
Hospitalized 
patients  NR 
Variable 
(6 cases 
under 2 
years) 
2.3% Absent 
Fever, cough, 
wheezing, respiratory 
distress, diarhoea 
[28, 
88] 
Canada 
Throat swab, 
nasopharygeal 
swab, lung 
autopsy 
RT-PCR 
Winter 
(January-
March) 
patients with 
ARI  525 
1 month-
100 
years 
3.6%(13 
males and 6 
females) 
Absent 
Fever, rhinitis cough, 
sore throat, 
bronchiolitis 
[45] 
France NR RT-PCR  Winter 
(February) 
Hospitalized 
patients for 
ARI 
300 
Variable 
(18 cases 
under 2 
years) 
9.3% Absent 
Fever, rhinitis, 
bronchiolitis, 
digestive problems, 
otitis, pharyngitis and 
conjuctivitis 
[29] 
Germany 
Naso 
pharyngeal 
secretions 
Real-time 
RT-PCR  Winter 
Population-
based 
(Inpatients+ 
outpatients) 
949  < 3 years  5.2%  Present 
Croup 
Bronchitis 
Bronchiolitis 
[52, 
53] 
China, 
Hong 
Kong 
Nasopharyngea
l aspirate  RT-PCR  Spring and 
summer 
Hospitalized 
patients for 
ARI 
587  6-57 
months  2.6% Present 
Croup 
Fever 
Rash 
Sore throat 
Cough rhinitis 
shortness of breath 
Hoarseness 
Asthma exacerbations 
Seizures 
[26] 
Italy  Nasopharyngea
l aspirate  RT-PCR 
Winter 
(December
-February) 
Hospitalized 
infants for 
ARI 
150  <2 years  1.86%  Present 
Bronchiolitis  
Pneumonia 
Bronchospasm 
Wheezing rhinitis 
Bronchiolitis 
laryngitis 
[51] 
Japan NR  RT-PCR  January-
March 
NR 419  NR  5  cases  ND  ND  [49] 
Korea  Nasopharyngea
l aspirate  RT-PCR  April-May 
Children 
with lower 
respiratory 
tract 
infection 
515    1.6%  25% 
Fever, rales wheezing 
Pneuminia 
Croup 
Asthma exacerbation 
[71] 
Taiwan  Nasopharyngea
l aspirate 
Quantitativ
e RT-PCR 
Peak in 
October 
Hospitalized 
patients for 
ARI 
539  < 3 years  1.3% Present 
Fever, cough , croup, 
and straidor 
[47] 
Thailand  Nasopharyngea
l aspirate 
RT-PCR  Autumn 
Hospitalized 
patients with 
pneumonia+ 
out patients 
with flu like 
illnesses 
1890  1month-
65 years 
7/734  
(first year) 
1/1156 
(second 
year 
Present 
Cough, fever, straidor, 
croup 
[46] Understanding Human Coronavirus HCoV-NL63  The Open Virology Journal, 2010, Volume 4    81 
Croup children  present with pharangitis, sore throat and 
hoarseness of voice, and are considered for hospitalization. 
Of the rare findings, a group has reported the association 
between HCoV-NL63 and Kawasaki disease, a form of 
childhood vasculitis that is presented as fever, polymorphic 
exanthema, oropharyngeal erythema and bilateral 
conjuctivitis [65]. However, others fail to report on this 
association [66, 67]. 
  It is noteworthy to say that the report of symptoms in 
young children, who represent the majority of patients, is 
based mainly on parental observations, where other possible 
subjective signs and symptoms fail to be recognized by the 
parents. Moreover, most of the studies were conducted on 
patients reporting to hospitals suffering from acute 
respiratory tract infection. To date, there are only few 
population-based studies and the question arises whether 
larger numbers of such studies might reveal the involvement 
of other body systems. 
5. LABORATORY DIAGNOSIS AND DETECTION 
  It is difficult to distinguish clinical symptoms caused by 
HCoV-NL63 from those caused by many of the other human 
viruses, which could make diagnosis and detection of the 
virus complex. Treatment of patients without a clear 
diagnosis could result in implementation of expensive and 
disruptive public health measures, as well as to an increased 
spread of the disease [68]. Therefore, improved surveillance 
and diagnosis of respiratory illness could reduce health-care 
costs drastically [68-70]. 
5.1. Detection of Viral RNA 
  Due to its high specificity and sensitivity, reverse 
transcription polymerase chain reaction (RT-PCR) and other 
nucleic acid tests are the preferred methods for diagnosis of 
coronavirus infections, such as SARS-CoV [15]. The 
majority of nucleic acid amplification tests is designed with 
the ORF1a/1b, which is genetically stable in coronaviruses, 
and the nucleocapsid (N) or spike (S) genes (Table 1) [25, 
26, 28, 30, 45, 46, 64, 67, 71-73]. Based on in vitro 
coronavirus expression studies, the N gene has the 
theoretical advantage of being more abundant in infected 
cells and therefore of higher sensitivity for PCR assays, but 
this has not been clearly proven in clinical studies [74]. RT-
PCR of nasopharyngeal samples, both frozen and fresh, is 
the most popular choice for detection of HCoV-NL63 (Table 
1) and viral culture is frequently used for confirmation of 
infection [67, 73]. 
5.2. Antigen and Antibody Detection Assays 
  Serum samples have been screened for antibodies against 
HCoV-NL63 using enzyme-linked immunosorbent assays 
(ELISA) [75, 76]. An ELISA assay based on the N protein 
showed high seropositive results for serum samples from 
children younger than 20 years old [76]. Interestingly, the 
presence of maternally-acquired N-directed antibodies was 
detected in serum by ELISA [75, 76], usually decreasing 
within the first 4-5 months of life [76]. Potent neutralizing 
activity directed against HCoV-NL63 S protein was detected 
in virtually all serum samples from patients eight years of 
age or older, suggesting that HCoV-NL63 infection of 
humans is common and usually acquired during childhood 
[42]. Alarmingly, SARS-CoV infections appear to stimulate 
cross-reactive antibody responses to other human 
coronaviruses, including HCoV-NL63 [77]. Such cross 
reaction between human coronaviruses has been reported 
previously for immunoflourescence and complement fixation 
tests [78, 79]. In fact, false positive results were also 
reported for SARS-CoV detection using ELISA tests based 
on the recombinant N antigen [80]. This cross-reactivity is 
most likely due to the presence of cross-reactive antigenic 
epitopes of the coronaviruses [77]. An awareness of this 
(Table 1) contd….. 
Country  Specimen Type 
Method 
of 
Detection 
Seasonal 
Prevalence 
Type of 
Study 
Number of 
Patients 
Involved in 
the Study 
(Sample 
Size) 
Age 
Incidence 
of HCoV-
NL63 
Co-
Infection  Symptoms  Refs. 
South 
Africa  Nasal swab  RT-PCR  NR ND  238 
Median 
age= 
12.4 
months 
8.3% Present 
Wheezing 
[89] 
Switzerland  Nasopharyngeal 
swab  RT-PCR  Cold 
months  outpatients  82 
Neonates 
(less than 
1 year) 
7%  ND 
Cough, wheeze, fever, 
rhinitis , otitis, 
tonsillitis 
[60] 
Sweden  Nasopharyngeal 
aspirate  RT-PCR  NR 
Oupatients 
(Children 
attending to 
pediatric 
department) 
212 ND  6% ND 
ND 
[90] 
USA  Respiratory 
specimens 
RT-PCR 
Mostly 
January-
February 
Both 
ambulatory 
and 
hospitalized 
patients for 
ARI 
895  < 5 years  8.8%  Present 
Cough, rhinnorhoea, 
tachpnea, fever, 
abnormal breath 
sounds, hypoxia 
[91] 
NR: Not Reported. 
ND: Not Done. 82    The Open Virology Journal, 2010, Volume 4  Abdul-Rasool and Fielding 
cross-reactivity is important when developing antigen- 
and/or antibody-diagnostic assays and selecting the most 
suitable antigen or antigen target is important. 
6. CONCLUSION 
  The discovery of the HCoV-NL63 and other novel 
human coronaviruses does not necessarily represent a sudden 
increase in emerging infections by ‘new’ coronaviruses. In 
fact, in the early 1960’s, viral agents causing upper 
respiratory tract infections were isolated from patients and 
were subsequently shown to be coronaviruses by electron 
microscopy. At least four of these were shown to be 
serologically distinct from the known coronaviruses at the 
time [10, 11, 81]. However, with the clinical samples of 
these no longer available for study, it will never be known 
whether these ‘old’ viruses and the ‘new’ viruses represent 
the same strains [82]. 
  Molecular clock analysis is the average rate at which a 
species' genome accumulates mutations and is used to 
measure that species’ evolutionary divergence. The 
reliability of molecular dating is dependent on the validity of 
the molecular clock hypothesis, which assumes that the 
substitution rate is roughly constant [83], with an average 
substitution rate for coronaviruses estimated to be 10
 4 
substitutions per year per site [84, 85]. With the lack of 
sufficient sequence data available for HCoV-NL63, the 
substitution rate for HCoV-229E, using partial sequences of 
the S gene from different known dates, was calculated. Then, 
assuming a constant evolutionary rate in time and a constant 
evolutionary rate between the branches for HCoV-NL63 and 
HCoV229E, the time to their most recent common ancestor 
was dated to the 11
th century [24]. This shows that HCoV-
NL63 has been present in the human population for 
centuries. In support of this finding, the virus described by 
Fouchier et al. was originally isolated from an eight-month 
old child in 1988 [19]. More recent studies in the 
Netherlands also supported the notion that only SARS-CoV 
has recently been introduced to the human population from 
an animal source, while HCoV-NL63 has been circulating in 
humans for a while [86]. With the exception of SARS-CoV, 
the coronaviruses infecting humans are not well studied. 
This is partly due to the prevailing view that they are only 
involved in mild respiratory tract infections. The 
introduction of sensitive molecular and cell biology 
techniques have aided in identifying three ‘new’ human 
coronaviruses, which has improved our understanding of the 
classification of the coronaviruses. These modern tools now 
need to be developed further to make the sensitive and 
accurate detection of coronaviruses in clinical samples 
possible. This would increase our understanding of the 
extent to which coronaviruses affect human health. 
Importantly, Donaldson and colleagues has recently reported 
the assembly of a full-length infectious HCoV-NL63 clone, 
which will make the study of this virus easier, improving our 
understanding of the role of each of the proteins encoded by 
the HCoV-NL63 genome [87]. In the long run, molecular 
and cell biology tools could help elucidate the link, if any, 
between human coronaviruses and human diseases of the 
respiratory tract, the vascular system, the central nervous 
system and the gastrointestinal tract [82]. 
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ABBREVIATIONS 
HCoV =  Human  coronavirus 
HCoV-NL63 = Human  coronavirus  HCOV-NL63 
CoVs =  Coronaviruses 
Kbs =  Kilobases 
S =  Spike  protein 
E =  Envelope  protein 
M =  Membrane  protein 
N =  Nucleocapsid  protein 
SARS-CoV  =  Severe acute respiratory syndrome  
     coronavirus 
ORFs  =  Open reading frames 
VIDISCA =  Virus  discovery  cDNA-ALFP 
TGEV  =  Transmissible gastroenteritis virus 
PDEV  =  Porcine diarrhea virus 
FIPV  =  Feline infectious peritonitis virus 
MHV  =  Mouse hepatitis virus 
sg =  Subgenomic 
HR =  Heptad  repeat 
kDa =  KiloDaltons 
ACE2  =  Angiotensin converting enzyme 2 
RSV  =  Respiratory syncytial virus 
hMPV =  Human  metapneumovirus 
RT-PCR  =  Reverse transcription polymerase chain  
     reaction 
ELISAs  =  Enzyme-linked immunosorbent assays 
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